Connecting METTL3 and intratumoural CD33+ MDSCs in predicting clinical outcome in cervical cancer

Table 2 Correlations the expression of METTL3, CD33 and clinical parameters in total 197 cervical cancer patients

Clinicopathologic parameter	Total case	High METTL3 levels in tumor (%)	P	High METTL3 levels in tumor-infiltrating immune cells (%)	P	High density of CD33⁺ MDSCs (%)	P
Age
≤ 44 (years)	86	31 (43.7%)	0.999^a	41 (47.7%)	0.524^a	46 (53.5%)	0.672^a
> 44 (years)	111	40 (56.3%)		58 (52.3%)		56 (50.5%)
T1	147	59 (40.1%)	0.040^a	81 (55.1%)	0.020^a	78 (53.1%)	0.536^a
T2–4	50	12 (24.0%)		18 (36.0%)		24 (48.0%)
N status
N0	173	64 (37.0%)	0.454^a	88 (50.9%)	0.644^a	88 (50.9%)	0.493^a
N1	24	7 (29.2%)		11 (45.8%)		14 (58.3%)
Clinical stage
I	127	47 (37.0%)	0.703^a	68 (53.5%)	0.214^a	63 (49.6%)	0.412^a
II–IV	70	24 (34.3%)		31 (44.3%)		39 (55.7%)

ISSN: 1479-5876